NZ572186A - N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them - Google Patents

N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them

Info

Publication number
NZ572186A
NZ572186A NZ572186A NZ57218603A NZ572186A NZ 572186 A NZ572186 A NZ 572186A NZ 572186 A NZ572186 A NZ 572186A NZ 57218603 A NZ57218603 A NZ 57218603A NZ 572186 A NZ572186 A NZ 572186A
Authority
NZ
New Zealand
Prior art keywords
indole
bromo
methylpiperazin
mass
ylmethyl
Prior art date
Application number
NZ572186A
Other languages
English (en)
Inventor
Venkata Satya Nirogi Ramakrishna
Vikas Shreekrishna Shirsath
Rama Sastri Kambhampati
Venkata Satya Veerabhadra Rao
Venkateswarlu Jasti
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of NZ572186A publication Critical patent/NZ572186A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
NZ572186A 2002-11-28 2003-06-05 N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them NZ572186A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN884MA2002 2002-11-28

Publications (1)

Publication Number Publication Date
NZ572186A true NZ572186A (en) 2010-02-26

Family

ID=40184827

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ572186A NZ572186A (en) 2002-11-28 2003-06-05 N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
NZ540840A NZ540840A (en) 2002-11-28 2003-06-05 N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ540840A NZ540840A (en) 2002-11-28 2003-06-05 N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them

Country Status (21)

Country Link
US (1) US7875605B2 (enExample)
EP (1) EP1581492B1 (enExample)
JP (1) JP4559230B2 (enExample)
KR (1) KR100818508B1 (enExample)
CN (2) CN1720225B (enExample)
AT (1) ATE401307T1 (enExample)
AU (1) AU2003237599B2 (enExample)
BR (2) BRPI0318799B8 (enExample)
CA (1) CA2509982C (enExample)
CY (1) CY1108786T1 (enExample)
DE (1) DE60322266D1 (enExample)
DK (1) DK1581492T3 (enExample)
EA (1) EA011320B1 (enExample)
ES (1) ES2310243T3 (enExample)
MX (1) MXPA05005701A (enExample)
NO (2) NO330341B1 (enExample)
NZ (2) NZ572186A (enExample)
PT (1) PT1581492E (enExample)
SI (1) SI1581492T1 (enExample)
WO (1) WO2004048330A1 (enExample)
ZA (1) ZA200504043B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003208711A1 (en) * 2002-02-12 2003-09-04 Akzo Nobel N.V. 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders
WO2005005439A1 (en) * 2003-07-09 2005-01-20 Suven Life Sciences Limited Benzothiazino indoles
HRP20090419T1 (hr) 2004-01-02 2009-09-30 Suven Life Sciences Limited Novi indeno[2,1a]indeni i izoindol[2,1-a]indoli
BRPI0614692A2 (pt) 2005-07-29 2009-05-19 Hoffmann La Roche derivados de indol-3-il-carbonil-piperidina e piperazina
WO2007020653A1 (en) * 2005-08-12 2007-02-22 Suven Life Sciences Limited Thioether derivatives as functional 5-ht6 ligands
BRPI0520579B8 (pt) 2005-08-12 2021-05-25 Suven Life Sciences Ltd composto, processo para a preparação de um composto e composição farmacêutica
WO2007020654A1 (en) 2005-08-16 2007-02-22 Suven Life Sciences An improved process for the preparation of losartan
US20100041669A1 (en) * 2007-01-08 2010-02-18 Venkata Satya Nirogi Ramakrishna 4-(heterocyclyl)alkyl-n-(arylsulfonyl)indole compounds and their use as 5-ht6 ligands
DK2114878T3 (da) 2007-01-08 2011-03-14 Suven Life Sciences Ltd 5-(Heterocyclyl)alkyl-N-(arylsulfonyl)indolforbindelser og deres anvendelse som 5-HT6-ligander
WO2008136017A1 (en) 2007-05-03 2008-11-13 Suven Life Sciences Limited Aminoalkoxy aryl sulfonamide compounds and their use as 5-ht6 ligands
US7807705B2 (en) * 2007-05-18 2010-10-05 The Ohio State University Research Foundation Potent indole-3-carbinol-derived antitumor agents
EP2200980B9 (en) 2007-10-26 2011-12-28 Suven Life Sciences Limited Amino arylsulfonamide compounds and their use as 5-ht6 ligands field of invention
WO2010032257A1 (en) 2008-09-17 2010-03-25 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands
EA019496B1 (ru) 2008-09-17 2014-04-30 Сувен Лайф Сайенсиз Лимитед Арилсульфонамидные аминосоединения и их применение в качестве лигандов 5-ht
WO2011019738A1 (en) * 2009-08-10 2011-02-17 Galenea Corporation Compounds and methods of use thereof
US8153680B2 (en) * 2009-08-25 2012-04-10 The Ohio State University Research Foundation Alkyl indole-3-carbinol-derived antitumor agents
NZ601284A (en) 2010-01-05 2014-03-28 Suven Life Sciences Ltd Sulfone compounds as 5-ht6 receptor ligands
CN102093149A (zh) * 2010-12-08 2011-06-15 天津理工大学 一种促进氰基快速水解制备羧酸类化合物的方法
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
KR101534136B1 (ko) * 2013-06-11 2015-07-07 이화여자대학교 산학협력단 인돌 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 5-ht6 수용체 관련 질환의 예방 또는 치료용 약학적 조성물
CN105814020B (zh) 2013-12-02 2018-04-17 苏文生命科学有限公司 用于大规模生产1‑[(2‑溴苯基)磺酰基]‑5‑甲氧基‑3‑[(4‑甲基‑1‑哌嗪基)甲基]‑1h‑吲哚二甲磺酸盐一水合物的方法
JP6454346B2 (ja) 2013-12-20 2019-01-16 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 芳香族複素環式化合物及び医薬におけるその応用
CA2953004C (en) 2014-07-08 2023-02-21 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
HRP20190446T1 (hr) * 2014-08-16 2019-05-03 Suven Life Sciences Limited Aktivni metabolit 1-[(2-bromofenil) sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1h-indol dimezilat monohidrata i dimezilat dihidrat sol aktivnog metabolita
CN114642667A (zh) * 2016-05-18 2022-06-21 苏文生命科学有限公司 纯5-ht6受体拮抗剂与乙酰胆碱酯酶抑制剂的组合
DK3458040T3 (da) 2016-05-18 2021-05-03 Suven Life Sciences Ltd Kombination af rene 5-ht6-receptorantagonister med nmda-receptorantagonist
KR102016120B1 (ko) 2016-05-18 2019-10-21 수벤 라이프 사이언시스 리미티드 순수한 5-ht6 수용체 길항제, 아세틸콜린에스테라제 저해제 및 nmda 수용체 길항제의 3중 조합물
HUE055452T2 (hu) 2016-10-03 2021-11-29 Suven Life Sciences Ltd 5-HT6 antagonista gyógyszerkészítmények
CN107174586B (zh) * 2017-02-21 2020-08-11 中国科学院昆明植物研究所 以芦竹碱衍生物为活性成分的药物组合物及其应用
JP6959371B2 (ja) 2017-07-03 2021-11-02 スヴェン・ライフ・サイエンシーズ・リミテッドＳｕｖｅｎ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｉｍｉｔｅｄ 純粋な５−ｈｔ６受容体アンタゴニストの新たな使用
EP4069232B1 (en) 2019-12-02 2025-12-24 Suven Life Sciences Limited Masupirdine for treating behavioral and psychological symptoms in dementia
ES3036880T3 (en) 2019-12-02 2025-09-25 Suven Life Sciences Ltd Combinations of masupirdine with donepezil or memantine for treating behavioral and psychological symptoms in patients with dementia
CN111362858B (zh) * 2020-03-16 2021-05-11 东莞市东阳光新药研发有限公司 芳杂环类衍生物的盐及其用途
CN111233737B (zh) * 2020-03-16 2021-05-11 东莞市东阳光新药研发有限公司 芳杂环类衍生物的盐及其用途
KR102347372B1 (ko) 2020-12-14 2022-01-07 (주)케이메디켐 신규한 인돌 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물
CN115504925B (zh) * 2021-06-22 2024-03-12 广东药科大学 一类ppar激动剂、其制备方法及其作为药物的用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1305458A (enExample) 1969-02-26 1973-01-31
ZA795239B (en) 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
BE889931A (fr) 1980-08-12 1982-02-11 Glaxo Group Ltd Derives indoliques, leur preparation et leurs applications en tant que medicaments
GB8600397D0 (en) 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8724912D0 (en) 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
GB8819024D0 (en) 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
JPH04208263A (ja) * 1990-01-02 1992-07-29 Fujisawa Pharmaceut Co Ltd インドール誘導体およびそれらの製造法
IL96891A0 (en) 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
CA2042295A1 (fr) 1990-05-15 1991-11-16 Jacques Chauveau Derives de mediateurs endogenes, leurs sels, procede de preparation, applications, et compositions les renfermant
DE69132691T2 (de) 1990-06-07 2002-06-20 Astrazeneca Ab, Soedertaelje Indolderivate als 5-HT1-like Agonisten
SK278998B6 (sk) 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
TW263508B (enExample) 1991-02-12 1995-11-21 Pfizer
GB9113802D0 (en) 1991-06-26 1991-08-14 Smithkline Beecham Plc Medicaments
JP3223193B2 (ja) 1991-08-09 2001-10-29 株式会社日清製粉グループ本社 インドール誘導体およびそれらを有効成分とする抗癌剤耐性克服物質
GB9210400D0 (en) 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
KR940007001A (ko) 1992-09-16 1994-04-26 최승주 새로운 n-신나모일-2-메틸-5-메톡시-3-인돌 아세트산 에스테르, 그 제조방법 및 이를 함유하는 약학적 제제
CA2194984C (en) 1994-07-26 2002-07-02 John Eugene Macor 4-indole derivatives as serotonin agonists and antagonists
EP1173432B9 (en) * 1999-04-21 2008-10-15 NPS Allelix Corp. Piperidine-indole compounds having 5-ht6 affinity
JP2000344744A (ja) * 1999-06-04 2000-12-12 Ss Pharmaceut Co Ltd アセトフェノン誘導体およびその製法
PE20020276A1 (es) * 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
CN1317276C (zh) 2000-09-29 2007-05-23 中国科学院上海药物研究所 一类吲哚基哌啶类化合物及其制备方法和用途
NZ524675A (en) * 2000-10-20 2004-09-24 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-N1-(benzensulfonyl) indoles and their use in therapy
EP1335722B1 (en) * 2000-11-24 2006-08-30 Smithkline Beecham Plc Indolyl-sulfonyl- compounds useful in the treatment of cns disorders
EP1351688A4 (en) * 2000-12-11 2006-01-04 Smithkline Beecham Corp UROTENSIN-II RECEPTOR ANTAGONISTS
DK1355900T3 (da) * 2000-12-22 2006-09-11 Wyeth Corp Heterocyclylalkylindol- eller -azaindolforbindelser som 5-hydroxytryptamin-6-ligander
US6818655B2 (en) * 2001-01-26 2004-11-16 Smithkline Beecham Corporation Urotensin-II receptor antagonists
AU2003208711A1 (en) * 2002-02-12 2003-09-04 Akzo Nobel N.V. 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders

Also Published As

Publication number Publication date
WO2004048330A1 (en) 2004-06-10
NO330341B1 (no) 2011-03-28
EA200500881A1 (ru) 2005-12-29
NO20085054L (no) 2005-08-25
BRPI0315959B8 (pt) 2018-01-16
CA2509982C (en) 2011-11-08
ZA200504043B (en) 2006-07-26
NO335015B1 (no) 2014-08-25
PT1581492E (pt) 2008-09-19
WO2004048330A8 (en) 2005-10-27
CA2509982A1 (en) 2004-06-10
US7875605B2 (en) 2011-01-25
JP2006514011A (ja) 2006-04-27
AU2003237599B2 (en) 2009-06-18
CN101544592A (zh) 2009-09-30
CY1108786T1 (el) 2014-04-09
HK1133002A1 (en) 2010-03-12
CN1720225B (zh) 2011-05-18
KR100818508B1 (ko) 2008-03-31
NO20052737D0 (no) 2005-06-08
EP1581492B1 (en) 2008-07-16
AU2003237599A1 (en) 2004-06-18
SI1581492T1 (sl) 2008-12-31
DK1581492T3 (da) 2008-11-10
BRPI0315959C1 (pt) 2021-05-25
EP1581492A1 (en) 2005-10-05
KR20050086868A (ko) 2005-08-30
EA011320B1 (ru) 2009-02-27
US20060223890A1 (en) 2006-10-05
DE60322266D1 (de) 2008-08-28
NO20052737L (no) 2005-08-25
ES2310243T3 (es) 2009-01-01
HK1083217A1 (en) 2006-06-30
JP4559230B2 (ja) 2010-10-06
CN1720225A (zh) 2006-01-11
NZ540840A (en) 2008-12-24
BRPI0318799B8 (pt) 2021-05-25
BRPI0318799B1 (pt) 2019-06-25
CN101544592B (zh) 2013-08-21
MXPA05005701A (es) 2005-08-16
BRPI0315959B1 (pt) 2017-12-19
ATE401307T1 (de) 2008-08-15
BR0315959A (pt) 2005-09-13

Similar Documents

Publication Publication Date Title
NZ572186A (en) N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
RU2134266C1 (ru) Производные 5-арилиндола и их применение в качестве агонистов серотонина (5-нт1)
US7022708B2 (en) 4-piperazinyl benzenesulfonyl indoles and uses thereof
CA2507505C (en) N-arylsulfonyl-3-aminoalkoxyindoles
AU2003292510A1 (en) Tetracyclic 3-substituted indoles having serotonin receptor affinity
CA2490254C (en) Novel tetracyclic arylsulfonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
NZ551292A (en) 3-Amino-1-arylpropyl indoles as monoamine reuptake inhibitor
CN102015642A (zh) 新的3-氨基烷基-1,3-二氢-2h-吲哚-2-酮衍生物、其制备方法和其治疗用途
WO2004048331A1 (en) N-arylalkyl-3-aminoalkoxyindoles and their use as 5-ht ligands
WO2004108671A1 (en) Substituted indoles with serotonin receptor affinity, process for their preparation and pharmaceutical compositions containing them
CN101679249A (zh) 作为组胺h3受体调节剂的吲哚和苯并噻吩化合物
CZ172796A3 (en) 3-substituted 1-arylindole derivatives, their use and pharmaceutical compositions containing thereof
HK1133002B (en) Alternative process for preparing n-arylsulfonyl-3-substituted indoles
HK1083217B (en) N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 05 JUN 2016 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20130301

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JUN 2017 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20160307

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JUN 2018 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20170306

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JUN 2019 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20180305

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JUN 2020 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20190312

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JUN 2021 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20200329

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JUN 2022 BY AJ PARK

Effective date: 20210428

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JUN 2023 BY AJ PARK

Effective date: 20220407

EXPY Patent expired